Cancer screening in primary care

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vishal Devarkonda, M.B.B.S[2]

Overview

Worldwide, cancer is among the leading causes of morbidity and mortality; cancer contributed to approximately 8.2 million deaths in 2012, or an estimated 13% of overall deaths.[1] WHO expects a 70% increase in the number of new cancer cases over the next two decades.[2] The burden of cancer is substantial and increasing worldwide.[3] The incidence, prevalence, and mortality of specific cancers vary widely across countries as a result of variations in lifestyle risk factors (such as tobacco use, physical inactivity, excess body weight, reproductive patterns), the prevalence of carcinogenic infections (e.g., Hepatitis B, Hepatitis C, HPV), genetics, and the availability of health care resources.[3] In 2012, lung, prostate, colorectal, gastric, and liver carcinomas were the most common cancers among men, while breast, colorectal, lung, cervical, and gastric carcinomas were most common among women.[4] In 2014, the Agency for Healthcare Research and Quality estimated the direct medical costs associated with cancer in United States at $87.7 billion dollars.[5] It is estimated that HBV/HCV and HPV are responsible for up to 20% of cancer deaths in low- and middle-income countries.[6] It is also estimated that more than 30% of these cases are preventable.[6] Measures to prevent some types of cancer include effective screening, vaccination, and lifestyle modifications. This page provides information about the epidemiology and primary care aspects of preventing cancer.

Epidemiology

Worldwide, cancer is among the leading causes of morbidity and mortality; cancer contributed to approximately 8.2 million deaths in 2012, or an estimated 13% of overall deaths.[1] The most common type of cancer (excluding non-melanoma skin cancers) is breast cancer; it is estimated that there were more than 249,000 new cases in the United States in 2016. The next most common cancers are lung cancer and prostate cancer. In the United States, to qualify as a common cancer, the estimated annual incidence for 2016 had to be 40,000 cases or more.

The following table presents official estimates of new cases and deaths in the United States for each common cancer type:[7]

American Cancer Society: Cancer Facts & Figures 2016
Cancer Type Estimated New Cases Estimated Deaths
Breast 249,200 40,890
Lung (Including Bronchus) 224,390 158,080
Prostate 180,890 26,120
Colon and Rectal (Combined) 134,490 49,190
Bladder 76,960 16,390
Melanoma 76,380 10,130
Non-Hodgkin Lymphoma 72,580 20,150
Thyroid 64,300 1,980
Kidney (Renal Cell and Renal Pelvis) Cancer 62,700 14,240
Leukemia (All Types) 60,140 24,400
Endometrial 60,050 10,470
Pancreatic 53,070 41,780

Adulthood Cancers

Top 10 Cancers by Incidence and Mortality, 2013[8]
by Incidence by Mortality
Cancer type Incidence Cancer type Mortality
Female Breast 123.7 Lung and Bronchus 43.4
Prostate 101.6 Female Breast 20.7
Lung and Bronchus 59.4 Prostate 19.2
Colon and rectum 38.4 Colon and rectum 14.5
Corpus and Uterus 25.9 Pancreas 10.8
Melanomas of the Skin 20.7 Ovary 7.2
Urinary Bladder 20.0 Leukemias 6.7
Non-Hodgkin Lymphoma 18.5 Liver and Intrahepatic Bile duct 6.5
Kidney and Renal Pelvis 16.0 Non-Hodgkin Lymphoma 5.7
Thyroid 14.6 Corpus and Uterus 4.6

* Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population.

Most Common Cancers in the United States by Gender[9]
Male Female
Most Common (by Occurrence) Incidence Most Common (by Mortality) Mortality Most Common (by Occurrence) Incidence Most Common (by Mortality) [10] Mortality
Prostate cancer 101.6 Lung cancer 53.9 Breast cancer 123.7 Lung cancer 35.4
Lung cancer 69.8 Prostate cancer 19.2 Lung cancer 51.5 Breast cancer 20.7
Colorectal cancer 44.2 Colorectal cancer 17.3 Colorectal cancer 33.6 Colorectal cancer 12.1

* Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population.

Childhood Cancers

In 2013, the most commonly diagnosed cancers and leading causes of cancer-related death in children aged 0 to 19 years were leukemia and central nervous system cancers.[11]

Childhood Cancers[12]
Incidence Mortality
Cancer type 0-14 years 0-19 years 0-14 years 0-19 years
All cancers combined 16.8 18.0 2.1 2.3
Leukemias 4.8 4.3 0.6 0.6
Brain and Central nervous system cancer 3.6 3.2 0.7 0.7

* Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population.

Please click here to know more about the cancer epidemiology

Prevention

Effective measures for cancer prevention include:

Screening

Breast Cancer

United States Preventive Services Task Force Recommendations for Breast Cancer Screenings
Population Recommendation Grade
Women, 40 Years and Older The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older. I
Women, Age 50-74 Years The USPSTF recommends biennial screening mammography for women 50-74 years. B
Women, Before the Age of 50 Years The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms. C
Women, 75 Years and Older The USPSTF concludes that the current evidence is insufficient to assess the benefits and harms of screening mammography in women 75 years and older. I

Relevance of Breast Cancer Screening

Studies have reported that, for women of all age groups with an average risk, breast cancer screening was associated with a reduction in breast cancer mortality of approximately 20%, although there was an uncertainty in the quantitative estimates of outcomes for different breast cancer screening strategies in the United States.[13]

Please click here to learn more about Breast cancer screening.

Colon Cancer

United States Preventive Services Task Force Recommendations for Colon Cancer Screening
Population Recommendation Grade
Adults aged 50 to 75 years The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years. A
Adults aged 76 to 85 years The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient’s overall health and prior screening history.
  • Adults in this age group who have never been screened for colorectal cancer are more likely to benefit from screenings.
  • Screening would be most appropriate among adults who 1) are healthy enough to undergo treatment if colorectal cancer is detected and 2) do not have co-morbid conditions that would significantly limit their life expectancy.
C

Relevance of Colon Cancer Screenings

Studies have reported a 40% to 60% risk reduction for the incidence o colorectal cancer and mortality from colorectal cancer after screening colonoscopy.[14]

Please click here to know more about Colon cancer screening.

Cervical Cancer

United States Preventive Services Task Force Recommendations for Cervical Cancer Screening
Population Recommendation Grade
Women aged 21 to 65 (Pap Smear) or 30-65 (in combo with HPV testing) The USPSTF recommends screening for cervical cancer in women age 21 to 65 years with cytology (Pap smear) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years. A

Relevance of Cervical Cancer Screening

Studies have shown that, in patients undergoing regular cervical cancer screenings, approximately 70%-80% of cervical cancer deaths can be prevented.[15]

Please click here to learn more about Cervical cancer screening.

Lung Cancer

United States Preventive Services Task Force Recommendations for Lung Cancer Screening
Population Recommendation Grade
Adults aged 55-80, with a history of smoking The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. B

Lung caner screening relevance

The National Lung Screen Trial (NLST), a randomized controlled trial, involving 50,000 participants as demonstrated a 20% relative lung cancer mortality benefit.[16]

Please click here to learn more about lung cancer screening.

Vaccination

Vaccine Recommendation
HPV vaccine Age< 15 years Two doses of HPV vaccine at least six months apart.
Age> 15 years
  • Three doses of HPV vaccine over a span of 24 weeks, with a minimum of 4 weeks interval between the first two doses, and 12 weeks between second and third dose.
  • Young women can get HPV vaccine until they are 27 years old and young men can get HPV vaccine until they are 22 years old.[17]
Hepatitis B vaccine
  • All infants should receive their first dose of hepatitis B vaccine as soon as possible after birth, preferably within 24 hours, followed by two or three additional doses.
  • The vaccination schedule for children and adults involves 3 intramuscular injections, the second and third doses administered 1 and 6 months after the first.[17]

Relevance of the HPV Vaccine in Cancer Prevention

Studies have reported that the development of the 4vHPV vaccine has decreased the prevalence of HPV 6/11/16/18 cervical/vaginal infections, genital warts, low- and high-grade cytological abnormalities, CIN2, CIN3, and AIS among females in their teens and 20s.[18]

Please click here to learn more about the HPV vaccine.

Relevance of the Hepatits B Vaccine in Cancer Prevention

Strong evidence that hepatocellular cancer (HCC) can be prevented is provided by a cluster randomized controlled trial of the immunization of 75,000 newborns with hepatitis B virus (HBV) vaccine. After a median of about 25 years of follow-up, the incidence ratio of primary liver cancer in the vaccination-at-birth group versus the control group (68% of whom received catch-up vaccinations at ages 10–14 years) was 0.16 (95% confidence interval, 0.03–0.77).[19] These findings suggest that if HBV can be prevented, then much HCC can be prevented.

Please click here to learn more about the Hepatitis B vaccine.

Lifestyle modifications

Lifestyle modifications
Avoiding Tobacco Cigarette Smoking Lung cancer is the leading cause of cancer death, and almost all cases can be attributed to cigarette smoking. Compared to nonsmokers, current smokers are about 25 times more likely to die from lung cancer. Smoking causes between 80% and 90% of lung cancer deaths. Smoking also causes cancer of the mouth and throat, esophagus, stomach, colon, rectum, liver, pancreas, voicebox (larynx), trachea, bronchus, kidney and renal pelvis, urinary bladder, and cervix, and causes acute myeloid leukemia.[20][21]
Secondhand Smoke Adults who are exposed to secondhand smoke at home or at work experience an increase their risk of developing lung cancer of 20% to 30%. Concentrations of many cancer-causing and toxic chemicals are higher in secondhand smoke than in the smoke inhaled by smokers.

Please click here to learn more about smoking cessation

Please click here to learn more about lung cancer.

Protecting Your Skin Skin cancer is the most common kind of cancer in the United States. Exposure to ultraviolet (UV) rays from the sun and tanning beds appears to be the most important environmental factor involved with developing skin cancer. To help prevent skin cancer while still having fun outdoors, protect yourself by seeking shade; applying sunscreen; and wearing sun-protective clothing, a hat, and sunglasses.

Please click here to learn more about skin cancer.

Limiting Alcohol Intake
  • Studies around the world have shown that drinking alcohol regularly increases the risk of getting mouth, voice box, and throat cancers.
  • A large number of studies provide strong evidence that drinking alcohol is a risk factor for primary liver cancer, and more than 100 studies have found an increased risk of breast cancer with increasing alcohol intake. The link between alcohol consumption and colorectal (colon) cancer has been reported in more than 50 studies.[22]

Please click here to learn more about alcoholism.

Maintaining a Healthy Weight Research has shown that being overweight or obese substantially raises a person’s risk of getting endometrial (uterine), breast, prostate, and colorectal cancers. Overweight is defined as a body mass index (BMI) of 25 to 29, and obesity is defined as a BMI of 30 or higher.

Please click here to learn more about obesity management.

Getting Tested for Hepatitis C Hepatitis is inflammation of the liver, which is most often caused by a virus. In the United States, the most common type of viral hepatitis is Hepatitis C. Over time, chronic Hepatitis C can lead to serious liver problems including liver damage, cirrhosis, liver failure, or liver cancer. CDC recommends that anyone who was born between 1945 and 1965 get tested for Hepatitis C.

Please click here to learn more about Hepatitis C.

Please click here to learn more about Cancer prevention.

References

  1. 1.0 1.1 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
  2. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
  3. 3.0 3.1 Torre LA, Siegel RL, Ward EM, Jemal A (2016). "Global Cancer Incidence and Mortality Rates and Trends--An Update". Cancer Epidemiol Biomarkers Prev. 25 (1): 16–27. doi:10.1158/1055-9965.EPI-15-0578. PMID 26667886.
  4. "Cdc".
  5. "Agency of health research and quality".
  6. 6.0 6.1 "Who factsheets".
  7. "American Cancer Society: Cancer Facts and Figures 2016. Atlanta, Ga: American Cancer Society, 2016".
  8. "United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2016".
  9. "U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2016".
  10. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005). "Cancer statistics, 2005". CA Cancer J Clin. 55 (1): 10–30. PMID 15661684.
  11. [www.cdc.gov/uscs. "U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2016"] Check |url= value (help).
  12. "U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2016".
  13. Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S; et al. (2015). "Benefits and Harms of Breast Cancer Screening: A Systematic Review". JAMA. 314 (15): 1615–34. doi:10.1001/jama.2015.13183. PMID 26501537. Review in: Ann Intern Med. 2016 Mar 15;164(6):JC26
  14. Brenner H, Stock C, Hoffmeister M (2014). "Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies". BMJ. 348: g2467. doi:10.1136/bmj.g2467. PMC 3980789. PMID 24922745.
  15. Landy R, Pesola F, Castañón A, Sasieni P (2016). "Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study". Br J Cancer. 115 (9): 1140–1146. doi:10.1038/bjc.2016.290. PMC 5117785. PMID 27632376.
  16. National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD; et al. (2011). "Reduced lung-cancer mortality with low-dose computed tomographic screening". N Engl J Med. 365 (5): 395–409. doi:10.1056/NEJMoa1102873. PMC 4356534. PMID 21714641. Review in: Ann Intern Med. 2011 Nov 15;155(10):JC5-06
  17. 17.0 17.1 "Cdc-cancer-prevention vaccination".
  18. Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ; et al. (2016). "Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience". Clin Infect Dis. 63 (4): 519–27. doi:10.1093/cid/ciw354. PMC 4967609. PMID 27230391.
  19. Qu C, Chen T, Fan C, Zhan Q, Wang Y, Lu J; et al. (2014). "Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial". PLoS Med. 11 (12): e1001774. doi:10.1371/journal.pmed.1001774. PMC 4280122. PMID 25549238.
  20. "U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General, 2014".
  21. "International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans: Volume 100E: Personal Habits and Indoor Combustions. Lyon, France: International Agency for Research on Cancer; 2012".
  22. Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V; et al. (2007). "Carcinogenicity of alcoholic beverages". Lancet Oncol. 8 (4): 292–3. PMID 17431955.